Ceftriaxone Efficacy for Mycobacterium avium Complex Lung Disease in the Hollow Fiber and Translation to Sustained Sputum Culture Conversion in PatientsJOURNAL OF INFECTIOUS DISEASESIF4.52023-11-301OAAI
Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy developmentJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62023-02-166OAAI
Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasiiANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52021-04-196OAAI
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant TuberculosisANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52020-12-1616OAAI
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62019-11-1214OAAI
Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical modelsJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62019-04-3016OAAI
Once-a-week tigecycline for the treatment of drug-resistant TBJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62019-02-2814OAAI
Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant TuberculosisJOURNAL OF INFECTIOUS DISEASESIF4.52018-12-2819OAAI
The Sterilizing Effect of Intermittent Tedizolid for Pulmonary TuberculosisCLINICAL INFECTIOUS DISEASESIF7.32018-11-2828OAAI
Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-esistant TuberculosisCLINICAL INFECTIOUS DISEASESIF7.32018-11-2824OAAI
Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular TuberculosisCLINICAL INFECTIOUS DISEASESIF7.32018-11-2821OAAI
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant TuberculosisCLINICAL INFECTIOUS DISEASESIF7.32018-11-2889OAAI
D-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian DealCLINICAL INFECTIOUS DISEASESIF7.32018-11-2857OAAI
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to OrangesCLINICAL INFECTIOUS DISEASESIF7.32018-11-2824OAAI
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary TuberculosisCLINICAL INFECTIOUS DISEASESIF7.32018-11-2813OA
Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant TuberculosisCLINICAL INFECTIOUS DISEASESIF7.32018-11-2831OAAI
Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!CLINICAL INFECTIOUS DISEASESIF7.32018-11-2818OAAI
Antibacterial and Sterilizing Effect of Benzylpenicillin in TuberculosisANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52018-02-0133OAAI
Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease RecurrenceANTIMICROBIAL AGENTS AND CHEMOTHERAPYIF4.52017-11-01114OAAI
Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex diseaseJOURNAL OF ANTIMICROBIAL CHEMOTHERAPYIF3.62017-09-1165OAAI